Humacyte, Inc. insider trading

Every open-market purchase and sale by Humacyte, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $89,990 5 trades by 3 insiders 3 months later: median −33.5% (−38.3% vs S&P 500) Insider sales, 5 years $82,596 2 trades by 2 insiders 3 months later: median −37.5% (−42.4% vs S&P 500)

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Humacyte, Inc. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Humacyte, Inc.’s insiders pay?

From August 27, 2021 to August 19, 2026, 11 insiders reported 27 open-market purchases and 34 sales not made under a pre-set plan in Humacyte, Inc. Twelve months after each purchase was reported, the shares were −65.0% against the S&P 500 on average (median −74.8%), over 13 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −81.6% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 30, 2021 into $862 by November 2, 2026, −37.8% a year. It held shares 58% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,026 (+5.3% a year), and held throughout $17,942 (+12.0%).

Copying Humacyte, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Humacyte, Inc.'s insiders from August 30, 2021, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 58% of the time.

Humacyte, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Dougan Brady W	Director	5	−62.9% (4)	0%	15	−80.0% (5)	August 20, 2025
Niklason Laura E	President, CEO and Director	5	−62.9% (4)	0%	15	−80.0% (5)	August 20, 2025
Constantino Michael T.	Director	5	−75.4% (2)	0%	0	—	April 8, 2025
Binder Gordon M	Director	3	−74.8% (1)	0%	0	—	May 15, 2024
Sander Dale A.	CFO and Chief Corp. Deve. Off.	2	—	—	1	−92.5% (1)	April 14, 2025
Sebelius Kathleen	Director	2	—	—	1	−91.6% (1)	May 20, 2026
Prichard Heather Ledbetter	Chief Operating Officer	0	—	—	2	−76.0% (1)	June 3, 2024
Scheessele William John	Chief Commercial Officer	2	−36.3% (1)	0%	0	—	December 15, 2022
Jones Keith Anthony	Director	1	—	—	0	—	August 19, 2026
Parikh Shamik J	Chief Medical Officer	1	—	—	0	—	April 14, 2025
Wallace Max N.	Director	1	−80.2% (1)	0%	0	—	May 21, 2024

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Humacyte, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Humacyte, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −50.4% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
May 31, 2024	2 buying	−26.3%	−54.5%	−79.3%
May 31, 2022	3 buying	−24.7%	−40.0%	−41.6%
August 31, 2021	3 buying	−27.1%	−56.7%	−63.8%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Humacyte, Inc. · Funds · Politicians